On September 18, HENGRUI PHARMA rose 3.78% in regular trading, trading at HKD 46.02/share, with turnover of HKD 47.53 million.

On the news front, the company disclosed on September 17 that it completed its first A-share buyback, repurchasing 335,000 shares at a price range of RMB 43.10 to RMB 43.58 per share, spending approximately RMB 14.50 million. The buyback is part of a larger program approved on August 19, under which the company plans to repurchase between RMB 1 billion and RMB 2 billion worth of shares at a maximum price of RMB 81.78 per share over 12 months, with all repurchased shares earmarked for the A-share employee stock ownership plan.

Simultaneously, Hong Kong Exchange filings revealed that BlackRock increased its long position in HENGRUI PHARMA H-shares to 7.68% as of September 14, up from 7.17% reported on September 10 and 5.92% on September 2, reflecting a sustained institutional accumulation trend. The buyback initiation and continued buying by the world's largest asset manager reinforced positive sentiment, building on a series of recent pipeline milestones including multiple clinical trial approvals and marketing application acceptances.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)